Promising results rituximab in systemic sclerosis
The largest study of use in routine care of rituximab in patients with SSc showed significant changes on skin fibrosis but not on lung fibrosis. The safety profile was considered good and future studies are warranted into the possible role of rituximab in this patient population.
According to Prof. Allanore, (University of Paris Descartes University, France), a few small-sized observational studies have suggested that rituximab is a promising treatment in patients suffering from SSc. The study aimed to evaluate the outcomes of SSc patients receiving in routine care rituximab.
This was done as a retrospective longitudinal multicentre observational study in which eligible SSc patients were treated with rituximab upon the decision of their physician within the framework of European Scleroderma Trials and Research group (EUSTAR). This is an international scleroderma research network that aims to f...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Glucosepane Is a New Biomarker for the Severity of Osteoarthritis Next Article
Switching to Biosimilar bDMARDs Is Safe and Efficacious »
Table of Contents: EULAR 2018
Psoriasis and Psoriatic Arthritis
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.